Other Learning Activities

Recent activities

CPhA is pleased to partner with industry stakeholders to bring you a series of non-accredited learning activities to support your practice. Please view our recordings library below.

Protecting your at-risk patients from respiratory infections is as easy as 1-2-3 (September 14, 2022)
Preventing COVID-19 in high-risk patients: Are pre-exposure monoclonal antibodies an option for patients unlikely to respond to vaccines? (July 19, 2022)

Protecting your at-risk patients from respiratory infections is as easy as 1-2-3 (September 14, 2022)

This webinar was hosted by CPhA on behalf of Pfizer.

Watch Full Webinar

Speaker:

Michael Boivin, BSc. Phm, RPh, CDE, CTE
Clinical pharmacist consultant and president, CommPharm Consulting Inc.
Jen Belcher, Hon BSc, BSc Phm, MBA
Vice president, strategic initiatives & member relations, Ontario Pharmacists Association

Additional resources:

Slide deck

Every year, community-acquired pneumonia is associated with significant morbidity and mortality. Many patients are concerned about their risk of pneumonia but are unaware of the different vaccine options that have been shown to lower their risk. This webinar will review the impact of pneumococcal disease and the new vaccine options for at-risk patients. Attendees will leave this session with an understanding of who is a candidate for pneumococcal vaccines, as well as oral antiviral therapy once infected with Covid-19 and practical tips to discuss these options with their patients.

Preventing COVID-19 in high-risk patients: Are pre-exposure monoclonal antibodies an option for patients unlikely to respond to vaccines? (July 19, 2022)

This webinar was hosted by CPhA on behalf of AstraZeneca. The content was developed by the speaker and is not accredited.

Watch Full Webinar

Speaker:

Michael Boivin, BSc. Phm, RPh, CDE, CTE
Clinical pharmacist consultant and president, CommPharm Consulting Inc.
Dr. Brian Conway, MD, FRCPC
President and medical director, Vancouver Infectious Diseases Centre

Additional resources:

COVID-19 vaccines have been foundational in reducing the number of infections and severe outcomes associated with SARS-CoV2 infections. Unfortunately, a portion of individuals with immunocompromising conditions do not respond to these COVID-19 vaccines as well as healthy individuals. As public health measures (e.g., masking, physical distancing) are being removed across the country, patients with a lower immune response to vaccines are at elevated risk of infections and severe COVID-19 outcomes. Tixagevimab/Cilgavimab is a monoclonal antibody treatment that has been approved to be used to prevent COVID-19 infections in patients who are unable to mount an adequate immune response to COVID-19 vaccinations. This webinar will review the practical role of this treatment option to prevent COVID-19 in these patients at risk. This learning activity may be of interest to both community & hospital pharmacists, those supporting heme-oncology, transplant, and immune-compromised patient groups.